^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Lonsurf (trifluridine/tipiracil) (Thymidine phosphorylase inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
trifluridine/tipiracil 15mg/6.14mg and 20mg/8.19mg film-coated tablets (Lonsurf®)
Published date:
06/07/2021
Excerpt:
trifluridine/tipiracil (Lonsurf®) is accepted for restricted use within NHSScotland...As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Source:
Published date:
01/01/2020
Excerpt:
LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with...metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Source:
Published date:
04/25/2016
Excerpt:
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Source:
Title:
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
Published date:
01/27/2021
Excerpt:
CONTRADICTING EVIDENCE: Trifluridine–tipiracil is not recommended, within its marketing authorisation, for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more systemic treatment regimens.
Source:
Excerpt:
Trifluridine and tipiracil is recommended as a preferred category 1 treatment option for patients with recurrent or metastatic gastric cancer in the third-line or subsequent setting.
Source:
Title:
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
Published date:
05/22/2023
Excerpt:
In TAGS, third- or later-line trifluridine/tipiracil treatment demonstrated overall and progression-free survival and functioning benefits versus placebo and a consistent safety profile in patients with metastatic gastric/gastroesophageal junction cancer, regardless of prior treatment type.
DOI:
10.1007/s00432-023-04813-z
Trial ID:
Source:
Title:
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
Published date:
01/08/2022
Excerpt:
...patients receiving FTD/TPI experienced improved progression-free survival and stayed longer on treatment...The results of this subgroup analysis show the efficacy and tolerability of FTD/TPI treatment regardless of age in patients with mGC/GEJC who had received 2 or more prior treatments.
DOI:
10.1007/s10120-021-01271-9
Source:
Title:
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Excerpt:
Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer.
DOI:
10.1016/S1470-2045(18)30739-3
Trial ID:
